

NOVO NORDISK A S
Form 6-K
December 21, 2011

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

December 21, 2011

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Company Announcement

19 December 2011

Novo Nordisk A/S — Share repurchase programme

On 2 November 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 2 November 2011 to 31 January 2012.

Since the announcement as of 12 December 2011, the following transactions have been made under the programme:

	Number of	Average Transaction value,	
	shares purchase price	DKK	
Accumulated, last	1,880,000	1,148,001,165	
announcement			
12 December 2011	70,000	634.0350	44,382,450
13 December 2011	70,000	639.3200	44,752,400
14 December 2011	70,000	633.8400	44,368,800
15 December 2011	70,000	636.5200	44,556,400
16 December 2011	70,000	637.6700	44,636,900
Accumulated under	2,230,000	1,370,698,115	

the programme

With the transactions stated above, Novo Nordisk owns a total of 24,181,861 treasury shares, corresponding to 4.2% of the share capital. The total amount of shares in the company is 580,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 12.0 billion during 2011 and January 2012. As of 16 December 2011, Novo Nordisk has

Investor Relations 2880 Bagsværd +45 4444 8888 novonordisk.com 24256790

Denmark

Telefax:

+45 4444 6626

repurchased a total of 17,711,205 B shares equal to a transaction value of DKK 10,580,756,751.

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media:

Anne Margrethe Hauge

Tel: (+45) 4442 3450

amhg@novonordisk.com

Investors:

Klaus Bülow Davidsen

Tel: (+45) 4442 3176

klda@novonordisk.com

Frank Daniel Mersebach

Tel: (+45) 4442 0604

fdni@novonordisk.com

Lars Borup Jacobsen

Tel: (+45) 3075 3479

lbpj@novonordisk.com

In North America:

Ken Inchausti

Tel: (+1) 609 514 8316

kiau@novonordisk.com

Jannick Lindegaard

Tel: (+1) 609 786 4575

jlis@novonordisk.com

Company Announcement no 79 / 2011

Page 2 of 2

Novo Nordisk A/S Novo Allé

Telephone:

Internet:

CVR no:

Investor Relations 2880 Bagsværd +45 4444 8888 novonordisk.com 24256790

Denmark

Telefax:

+45 4444 6626

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: December 21, 2011

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer
